BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caers J, Withofs N, Hillengass J, Simoni P, Zamagni E, Hustinx R, Beguin Y. The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. Haematologica. 2014;99:629-637. [PMID: 24688111 DOI: 10.3324/haematol.2013.091918] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Tagliafico AS. Imaging in multiple myeloma: Computed tomography or magnetic resonance imaging? World J Radiol 2021; 13(7): 223-226 [PMID: 34367508 DOI: 10.4329/wjr.v13.i7.223] [Reference Citation Analysis]
2 Sachpekidis C, Mai EK, Goldschmidt H, Hillengass J, Hose D, Pan L, Haberkorn U, Dimitrakopoulou-strauss A. 18F-FDG Dynamic PET/CT in Patients with Multiple Myeloma: Patterns of Tracer Uptake and Correlation With Bone Marrow Plasma Cell Infiltration Rate. Clinical Nuclear Medicine 2015;40:e300-7. [DOI: 10.1097/rlu.0000000000000773] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
3 Fotiou D, Dimopoulos MA, Kastritis E. How We Manage Patients with Plasmacytomas. Curr Hematol Malig Rep 2018;13:227-35. [PMID: 29667156 DOI: 10.1007/s11899-018-0452-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
4 Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125:3059-3068. [PMID: 25838346 DOI: 10.1182/blood-2014-11-568907] [Cited by in Crossref: 178] [Cited by in F6Publishing: 167] [Article Influence: 29.7] [Reference Citation Analysis]
5 Dutoit JC, Verstraete KL. Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma. Skeletal Radiol 2017;46:733-50. [PMID: 28289855 DOI: 10.1007/s00256-017-2609-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
6 Mai EK, Hielscher T, Kloth JK, Merz M, Shah S, Raab MS, Hillengass M, Wagner B, Jauch A, Hose D, Weber MA, Delorme S, Goldschmidt H, Hillengass J. A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma. Haematologica 2015;100:818-25. [PMID: 25795721 DOI: 10.3324/haematol.2015.124115] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
7 Czyż J, Małkowski B, Jurczyszyn A, Grząśko N, Łopatto R, Olejniczak M, Czyż A, Jachalska A. 18F-fluoro-ethyl-tyrosine (18F-FET) PET/CT as a potential new diagnostic tool in multiple myeloma: a preliminary study. Contemp Oncol (Pozn) 2019;23:23-31. [PMID: 31061633 DOI: 10.5114/wo.2019.83342] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Wennmann M, Hielscher T, Kintzelé L, Menze BH, Langs G, Merz M, Sauer S, Kauczor HU, Schlemmer HP, Delorme S, Goldschmidt H, Weinhold N, Hillengass J, Weber MA. Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns. Cancers (Basel) 2021;13:961. [PMID: 33668879 DOI: 10.3390/cancers13050961] [Reference Citation Analysis]
9 Dupuis MM, Tuchman SA. Non-secretory multiple myeloma: from biology to clinical management. Onco Targets Ther 2016;9:7583-90. [PMID: 28008276 DOI: 10.2147/OTT.S122241] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 4.4] [Reference Citation Analysis]
10 Palma BD, Guasco D, Pedrazzoni M, Bolzoni M, Accardi F, Costa F, Sammarelli G, Craviotto L, De Filippo M, Ruffini L, Omedè P, Ria R, Aversa F, Giuliani N. Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20. Leukemia 2016;30:409-16. [PMID: 26419509 DOI: 10.1038/leu.2015.259] [Cited by in Crossref: 27] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
11 Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, Touzeau C, Abildgaard N, Terpos E, Heusschen R, Ocio E, Delforge M, Sezer O, Beksac M, Ludwig H, Merlini G, Moreau P, Zweegman S, Engelhardt M, Rosiñol L. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol 2018;11:10. [PMID: 29338789 DOI: 10.1186/s13045-017-0549-1] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 20.3] [Reference Citation Analysis]
12 Giaccone L, Brunello L, Festuccia M, Gilestro M, Maffini E, Ferrando F, Talamo E, Passera R, Boccadoro M, Omedè P, Bruno B. Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma. Bone Marrow Transplant 2015;50:511-6. [PMID: 25665043 DOI: 10.1038/bmt.2014.319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
13 Vincent L, Ceballos P, Plassot C, Méniane JC, Quittet P, Navarro R, Cyteval C, Szablewski V, Lu ZY, Kanouni T, Moreaux J, Cartron G, Klein B, Fegueux N. Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma. Blood Cancer J 2015;5:e341. [PMID: 26295611 DOI: 10.1038/bcj.2015.48] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
14 Di Giuliano F, Picchi E, Muto M, Calcagni A, Ferrazzoli V, Da Ros V, Minosse S, Chiaravalloti A, Garaci F, Floris R, Muto M. Radiological imaging in multiple myeloma: review of the state-of-the-art. Neuroradiology 2020;62:905-23. [DOI: 10.1007/s00234-020-02417-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
15 Hovhannisyan N, Dhilly M, Fidalgo M, Fillesoye F, Guillouet S, Sola B, Barré L. [18F]Fludarabine-PET in a murine model of multiple myeloma. PLoS One 2017;12:e0177125. [PMID: 28472196 DOI: 10.1371/journal.pone.0177125] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
16 Caers J, Fernández de Larrea C, Leleu X, Heusschen R, Zojer N, Decaux O, Kastritis E, Minnema M, Jurczyszyn A, Beguin Y, Wäsch R, Palumbo A, Dimopoulos M, Mateos MV, Ludwig H, Engelhardt M. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. Oncologist 2016;21:333-42. [PMID: 26921288 DOI: 10.1634/theoncologist.2015-0303] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
17 Patriarca F, Carobolante F, Zamagni E, Montefusco V, Bruno B, Englaro E, Nanni C, Geatti O, Isola M, Sperotto A, Buttignol S, Stocchi R, Corradini P, Cavo M, Fanin R. The Role of Positron Emission Tomography with 18F-Fluorodeoxyglucose Integrated with Computed Tomography in the Evaluation of Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2015;21:1068-73. [DOI: 10.1016/j.bbmt.2015.03.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
18 Wu C, Huang J, Xu W, Guan Y, Ling H, Mi J, Yan H. Discriminating Depth of Response to Therapy in Multiple Myeloma Using Whole-body Diffusion-weighted MRI with Apparent Diffusion Coefficient. Academic Radiology 2018;25:904-14. [DOI: 10.1016/j.acra.2017.12.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
19 Gibbs WN, Nael K, Doshi AH, Tanenbaum LN. Spine Oncology. Radiologic Clinics of North America 2019;57:377-95. [DOI: 10.1016/j.rcl.2018.10.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
20 Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 2017;18:e206-17. [PMID: 28368259 DOI: 10.1016/S1470-2045(17)30189-4] [Cited by in Crossref: 202] [Cited by in F6Publishing: 110] [Article Influence: 50.5] [Reference Citation Analysis]
21 Karampinos DC, Ruschke S, Dieckmeyer M, Diefenbach M, Franz D, Gersing AS, Krug R, Baum T. Quantitative MRI and spectroscopy of bone marrow. J Magn Reson Imaging 2018;47:332-53. [PMID: 28570033 DOI: 10.1002/jmri.25769] [Cited by in Crossref: 90] [Cited by in F6Publishing: 77] [Article Influence: 22.5] [Reference Citation Analysis]
22 Costachescu D, Ionita I, Borsi EC, Potre O, Potre C, Navolan DB, Blidisel A, Ionita H, Erimescu A, Pop GN, Malita DC. Whole-body diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient values as prognostic factors in multiple myeloma. Exp Ther Med 2021;22:827. [PMID: 34149873 DOI: 10.3892/etm.2021.10259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Van Den Berghe T, Verstraete KL, Lecouvet FE, Lejoly M, Dutoit J. Review of diffusion-weighted imaging and dynamic contrast-enhanced MRI for multiple myeloma and its precursors (monoclonal gammopathy of undetermined significance and smouldering myeloma). Skeletal Radiol 2021. [PMID: 34523007 DOI: 10.1007/s00256-021-03903-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Sachpekidis C, Hillengass J, Goldschmidt H, Wagner B, Haberkorn U, Kopka K, Dimitrakopoulou-Strauss A. Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. Eur J Nucl Med Mol Imaging 2017;44:50-62. [PMID: 27573638 DOI: 10.1007/s00259-016-3502-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
25 Galtseva IV, Davydova YO, Kapranov NM, Julhakyan HL, Mendeleeva LP. Minimal residual disease in multiple myeloma: Benefits of flow cytometry. Int J Lab Hematol. 2018;40:12-20. [PMID: 29058372 DOI: 10.1111/ijlh.12757] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
26 Ormond Filho AG, Carneiro BC, Pastore D, Silva IP, Yamashita SR, Consolo FD, Hungria VTM, Sandes AF, Rizzatti EG, Nico MAC. Whole-Body Imaging of Multiple Myeloma: Diagnostic Criteria. RadioGraphics 2019;39:1077-97. [DOI: 10.1148/rg.2019180096] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
27 Ulaner GA, Landgren CO. Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders. Best Pract Res Clin Haematol 2020;33:101148. [PMID: 32139013 DOI: 10.1016/j.beha.2020.101148] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
28 Basha MAA, Hamed MAG, Refaat R, AlAzzazy MZ, Bessar MA, Mohamed EM, Ahmed AF, Tantawy HF, Altaher KM, Obaya AA, Afifi AHM. Diagnostic performance of 18F-FDG PET/CT and whole-body MRI before and early after treatment of multiple myeloma: a prospective comparative study. Jpn J Radiol 2018;36:382-93. [PMID: 29671193 DOI: 10.1007/s11604-018-0738-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
29 Weberpals J, Pulte D, Jansen L, Luttmann S, Holleczek B, Nennecke A, Ressing M, Katalinic A, Merz M, Brenner H; GEKID Cancer Survival Working Group. Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21st century. Haematologica 2017;102:e229-32. [PMID: 28280077 DOI: 10.3324/haematol.2016.157768] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
30 Sherrod AM, Hari P, Mosse CA, Walker RC, Cornell RF. Minimal residual disease testing after stem cell transplantation for multiple myeloma. Bone Marrow Transplant 2016;51:2-12. [DOI: 10.1038/bmt.2015.164] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
31 Navarro SM, Matcuk GR, Patel DB, Skalski M, White EA, Tomasian A, Schein AJ. Musculoskeletal Imaging Findings of Hematologic Malignancies. Radiographics 2017;37:881-900. [PMID: 28388273 DOI: 10.1148/rg.2017160133] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
32 Corso A, Mangiacavalli S. Non-Secretory Myeloma: Ready for a new Definition? Mediterr J Hematol Infect Dis 2017;9:e2017053. [PMID: 28894562 DOI: 10.4084/MJHID.2017.053] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
33 Paiva B, García-sanz R, San Miguel JF. Multiple Myeloma Minimal Residual Disease. In: Roccaro AM, Ghobrial IM, editors. Plasma Cell Dyscrasias. Cham: Springer International Publishing; 2016. pp. 103-22. [DOI: 10.1007/978-3-319-40320-5_7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
34 Glasbey JC, Arshad F, Almond LM, Vydianath B, Desai A, Gourevitch D, Ford SJ. Gastrointestinal manifestations of extramedullary plasmacytoma: a narrative review and illustrative case reports. Ann R Coll Surg Engl 2018;100:371-6. [PMID: 29692194 DOI: 10.1308/rcsann.2018.0015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
35 Dutoit JC, Verstraete KL. MRI in multiple myeloma: a pictorial review of diagnostic and post-treatment findings. Insights Imaging 2016;7:553-69. [PMID: 27164915 DOI: 10.1007/s13244-016-0492-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 36] [Article Influence: 10.4] [Reference Citation Analysis]
36 D'Anastasi M, Grandl S, Reiser MF, Baur-Melnyk A. [Radiological diagnostics of multiple myeloma]. Radiologe 2014;54:556-63. [PMID: 24927658 DOI: 10.1007/s00117-013-2628-9] [Reference Citation Analysis]
37 Lückerath K, Lapa C, Albert C, Herrmann K, Jörg G, Samnick S, Einsele H, Knop S, Buck AK. 11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma. Oncotarget 2015;6:8418-29. [PMID: 25762625 DOI: 10.18632/oncotarget.3053] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
38 Ahmadi SA, Slotty PJ, Munoz-Bendix C, Steiger HJ, Cornelius JF. Early surgical occipitocervical stabilization for plasma cell neoplasms at the craniocervical junction: systematic review and proposal of a treatment algorithm. Spine J. 2016;16:91-104. [PMID: 26409418 DOI: 10.1016/j.spinee.2015.09.032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]